東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Converting an oncogenic protein into...

Constance, Jonathan Eric.

FindBook

Google Book

Amazon

博客來

Converting an oncogenic protein into an apoptotic factor: Targeting Bcr-Abl to the mitochondria.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Converting an oncogenic protein into an apoptotic factor: Targeting Bcr-Abl to the mitochondria./
作者:	Constance, Jonathan Eric.
面頁冊數:	288 p.
附註:	Source: Dissertation Abstracts International, Volume: 74-06(E), Section: B.
Contained By:	Dissertation Abstracts International74-06B(E).
標題:	Biology, Molecular. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3551904
ISBN:	9781267900357

Converting an oncogenic protein into an apoptotic factor: Targeting Bcr-Abl to the mitochondria.
Constance, Jonathan Eric.

Converting an oncogenic protein into an apoptotic factor: Targeting Bcr-Abl to the mitochondria. - 288 p.

Source: Dissertation Abstracts International, Volume: 74-06(E), Section: B.

Thesis (Ph.D.)--The University of Utah, 2013.

The advent of rational drug design to target a single molecular event, as so aptly demonstrated with tyrosine kinase inhibitor (TKI) therapy and Bcr-Abl, has set a precedent for the ability to attack malignancy directly at the level of the oncogenic event. However, in the last decade it has become clear that new therapeutic strategies for chronic myelogenous leukemia (CML) must move beyond the mere inhibition of Bcr-Abl's tyrosine kinase activity if a cure is to be found. TKI resistance, persistent leukemic stem cells, and the acute blast phase crisis remain major problems to be solved. This work describes the efforts to use the central leukemogenic protein of CML, Bcr-Abl (oncogenic event itself), to selectively destroy the diseased cells that harbor it.

ISBN: 9781267900357Subjects--Topical Terms:

1017719
Biology, Molecular.

Converting an oncogenic protein into an apoptotic factor: Targeting Bcr-Abl to the mitochondria.
LDR:03501nam 2200361 4500 001 1957149
005 20131112081704.5
008 150210s2013 ||||||||||||||||| ||eng d
020 $a 9781267900357
035 $a (UMI)AAI3551904
035 $a AAI3551904
040 $a UMI $c UMI
100 1 $a Constance, Jonathan Eric. $3 2091974
245 1 0 $a Converting an oncogenic protein into an apoptotic factor: Targeting Bcr-Abl to the mitochondria.
300 $a 288 p.
500 $a Source: Dissertation Abstracts International, Volume: 74-06(E), Section: B.
500 $a Advisers: Michael R. Franklin; Carol S. Lim.
502 $a Thesis (Ph.D.)--The University of Utah, 2013.
520 $a The advent of rational drug design to target a single molecular event, as so aptly demonstrated with tyrosine kinase inhibitor (TKI) therapy and Bcr-Abl, has set a precedent for the ability to attack malignancy directly at the level of the oncogenic event. However, in the last decade it has become clear that new therapeutic strategies for chronic myelogenous leukemia (CML) must move beyond the mere inhibition of Bcr-Abl's tyrosine kinase activity if a cure is to be found. TKI resistance, persistent leukemic stem cells, and the acute blast phase crisis remain major problems to be solved. This work describes the efforts to use the central leukemogenic protein of CML, Bcr-Abl (oncogenic event itself), to selectively destroy the diseased cells that harbor it.
520 $a The subcellular localization of Bcr-Abl determines its function. This is also true for Bcr-Abl's normal counterpart, c-Abl. When localized to the mitochondria, c-Abl is a potent inducer of cell death. However, c-Abl pro-death activity is disrupted in CML. The mitochondriolytic mechanism of `death-directed' c-Abl is unknown. Yet, under conditions of cell stress from a variety of sources (e.g., endoplasmic reticulum stress, genotoxic agents, and oxidative stress) active c-Abl migrates to the mitochondria causing dysfunction and cell death. Our direct targeting of c-Abl and Bcr-Abl to the mitochondria demonstrated the sufficiency of c-Abl alone to kill leukemia cells and of Bcr-Abl's ability to recapitulate this function.
520 $a The central hypothesis of this study is that forcing Bcr-Abl to the mitochondria will selectively induce the death of leukemic cells by converting Bcr-Abl into an apoptotic factor. This approach restores a defunct apoptotic pathway (i.e., the mitochondrial `death-directed' c-Abl pathway) and does not rely on the indirect engagement of (often dysregulated) cell death mechanisms like many chemotherapeutics. c-Abl requires a mitochondrial chaperone (protein kinase Cδ). Therefore, we designed a protein chaperone, the intracellular cryptic escort (iCE), for Bcr-Abl that selectively functions in the pro-oxidative environment of CML cells. Though, the iCE did not move Bcr-Abl to the mitochondria, it did synergistically and selectively kill CML cells as a combination with imatinib or alone was as toxic as high dose imatinib.
590 $a School code: 0240.
650 4 $a Biology, Molecular. $3 1017719
650 4 $a Health Sciences, Pharmacology. $3 1017717
650 4 $a Engineering, Biomedical. $3 1017684
690 $a 0307
690 $a 0419
690 $a 0541
710 2 $a The University of Utah. $b Pharmacology and Toxicology. $3 2091975
773 0 $t Dissertation Abstracts International $g 74-06B(E).
790 1 0 $a Franklin, Michael R., $e advisor
790 1 0 $a Lim, Carol S., $e advisor
790 1 0 $a Blumenthal II, Donald K. $e committee member
790 1 0 $a Moos, Philip $e committee member
790 1 0 $a Abel, E. Dale $e committee member
790 $a 0240
791 $a Ph.D.
792 $a 2013
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3551904